Hold Rating for Hims & Hers Health Amidst Competitive Pressure from Amazon’s Telehealth Services
Citi analyst Daniel Grosslight has maintained their neutral stance on HIMS stock, giving a Hold rating on November 6. Daniel ...
Hosted on MSN36m
These Stocks Moved the Most Today: Walt Disney, Super Micro, Cisco, ASML, JD.com, Tapestry, Intuitive Machines, Hims & Hers, and More
Hims & Hers Health declined 24% after Amazon.com announced it will charge $16 a month for generic hair loss pill finasteride.
The Information10m
Disney’s Streaming Profit Hopes Rest on More Price Increases
We got some good news from the poor old entertainment companies this earnings season. Video streaming is finally becoming a ...
Investor's Business Daily on MSN17m
Stock Market Today: Indexes Fall As Chevron Breaks Out; Will American Airlines Hit A Buy Zone? (Live Coverage)
Investors continued to see multiple shades of light red Thursday as biotechs continued to struggle in the wake of the ...
New FDA rules for TV drug ads: Simpler language and no distractions
Those ever-present TV drug ads showing patients hiking, biking or enjoying a day at the beach could soon have a different look: New rules require drugmakers to be clearer and ...
Amazon Gets Into the Boner Pill Business, Hims Stock Goes Limp
Amazon acquired primary care provider One Medical for $3.9 billion in 2022, and fills prescriptions through Amazon Pharmacy.
InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China
InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, today announced that the first subject has been dosed in ...